Loading…
← CockpitCompetitor Analysis › ADMA ADMA Biologics, Inc.Open in the cockpit ↗

ADMA Biologics, Inc.ADMACompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Makes plasma-derived immunoglobulin therapies for immunodeficiency and infectious disease patients.

Momentum leader 97
Mkt cap
$3.01B
US dollars, full cap
Free float
96%
of shares outstanding
$/day
$51.1M
20-day average traded
Fwd P/E
16.7×
forward earnings
ROIC−WACC
+27.5 pp
WACC 8.1%
Hurdle
-65 pp
Req g minus delivered
Next earnings
127 days
25 Mar 2027
Close · USD$13.56
1D-0.5%
1W+2.8%
1M+20.8%
3M+38.9%
6M+58.4%
YTD-25.7%
1Y-12.1%
ATR %4.8%
Beta-0.07
52w lowhigh33.7% off high

What ADMA Biologics does

Makes plasma-derived immunoglobulin therapies for immunodeficiency and infectious disease patients.

Collects plasma at its own centres, manufactures the immunoglobulin products itself, and sells them through specialty distributors, so profit depends on how much finished product each batch of plasma yields and on plasma cost. It bought its Boca Raton plasma and manufacturing assets from Biotest, a German company, in 2017.

Products and services

  • ASCENIV (immunoglobulin, primary immunodeficiency)
  • BIVIGAM (immunoglobulin)
  • Nabi-HB (hepatitis B immune globulin)

Customers

  • Immunologists/hospitals
  • Patients with primary immunodeficiency

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • Plasma-derived biologics

What could go right

  • Immunodeficiency diagnosis and treatment growth
  • Plasma supply chain expansion

What could go wrong

  • Plasma collection cost and supply constraints
  • Competitive immunoglobulin market

Moat: narrow (regulatory licence, scale, installed base). FDA-licensed plasma collection and fractionation capacity is capital-intensive and slow to replicate.

Headquarters: Ramsey, New Jersey, US · Founded: 2004 · Employees: 647

Named competitors

ADMA Biologics at a glance

Size ADMA Biologics (ADMA) is a United States Health Care company (Biotechnology) with a market value of $3.01B, the 1538th largest of 3,085 United States companies the cockpit tracks. Shares closed at $13.56 on 18 Nov 2026.

Performance Over six months the shares gained 58.4%, against -2.0% for the median peer and -2.2% for the United States market (cap-weighted) — 6th highest of 21 in its peer set.

Growth Revenue grew 6.3% over the last twelve months (peer median +18.3%); the operating margin is 44.9% (peer median -1.7%).

Valuation It trades at 16.7× forward earnings against a peer median of 29.9× (4th cheapest of 9).

Price implies For today's price to make sense, revenue must grow about -1% a year for seven years (Req g). Recent delivered growth is +65%, so the hurdle is -65 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 27.5 points above its cost of capital (8.1% WACC).

Short interest Short interest is 8.1% of the free float (30 Oct 2026).

Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012515021 May 202621 Aug 202618 Nov 2026ADMA 160Peer median 98
Six months, rebased to 100: ADMA Biologics against the median of its 20 peers (local-currency closes).

ADMA Biologics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$519M$510M$426M$258M$154M
Revenue growth—+20%+65%+68%—
Gross profit$356M$293M$219M$88.2M$34.5M
EBITDA$241M$200M$147M$30.0M-$32.5M
Net income$182M$147M$198M-$28.2M-$65.9M
Free cash flow$133M$27.8M$110M$4.03M-$73.4M
Capital expenditure$8.20M$22.9M$8.57M$4.98M$13.9M
Total debt$203M$79.9M$82.1M$141M$154M

Quarterly statements and history in the cockpit →

ADMA Biologics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%-25%0%+25%TLXDYNDNLIRUBICONXERS2228VIRPBAVA9688ELVN6919028300MBXIOVAXNCR688278ADMA6-month return →1-month return →
Up and to the right = strong over both horizons. ADMA Biologics is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%20×40×60×TLXRUBICONXERSVIRP002007BAVA600161688278ADMARevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. ADMA Biologics is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%0%25%50%75%XERSVIRP002007BAVA600161688278ADMAGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. ADMA Biologics is the large dot.

ADMA Biologics competitors and peer comparison

Head to head with its named competitors (ADMA vs GRF.MC vs 4502.T vs KMDA)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
ADMA Biologics ADMA$3.01B+58%+6%45%16.7×-0.8%
Grifols GRF.MC$7.48B+19%+1%16%13.1×7.1%
Takeda Pharmaceutical 4502.T$69.8B+30%+6%18%51.0×3.7%
Kamada KMDA$465M+3%+5%15%17.9×5.0%

How ADMA Biologics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

ADMA Biologics against its 20 peers (data as of 18 Nov 2026)
MeasureADMAPeer medianRank in peer set
1-month return+20.8%-3.3%3rd highest of 21
6-month return+58.4%-2.0%6th highest of 21
Distance from 52-week high-33.7%-27.8%8th lowest of 21
Revenue growth (TTM)+6.3%+18.3%8th lowest of 16
Operating margin44.9%-1.7%highest of 17
Forward P/E16.7×29.9×4th cheapest of 9
Growth the price implies (Req g, 7 yrs)-0.8%4.0%2nd least demanding of 7
Growth delivered (Del g)+64.6%+19.9%2nd highest of 7
Hurdle (Req g minus delivered)-65.4 pp-21.0 ppleast demanding of 7
ROIC minus cost of capital+27.5 pp-8.0 pphighest of 17
EV / EBITDA12.8×53.7×3rd cheapest of 6
Net debt / EBITDA0.3×1.1×2nd least indebted of 7

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
ADMA Biologics ADMAUnited States$3.01B+58%+6%45%16.7×-0.8%+64.6%
Telix Pharmaceuticals TLX.AXAustralia$2.99B-2%+27%-1%34.5×n/an/a
Dyne Therapeutics DYNUnited States$2.97B-10%n/an/an/an/an/a
Denali Therapeutics DNLIUnited States$2.95B-2%n/a-2,488%n/an/an/a
Rubicon Research RUBICON.NSIndia$2.94B+68%+37%21%66.6×n/an/a
Xeris Biopharma XERSUnited States$3.10B+173%+38%13%49.7×29.5%+70.2%
XtalPi 2228.HKHong Kong$2.87B-34%+4%-127%n/an/an/a
Virbac VIRP.PAFrance$3.20B-4%+4%15%16.6×5.8%+9.4%
Hualan Biological Engineering 002007.SZChina$3.20B-17%-11%17%26.7×15.8%-1.8%
Bavarian Nordic A/S BAVA.CODenmark$2.82B+23%-8%18%16.6×-4.3%+27.4%
Zai Lab 9688.HKHong Kong$2.79B+23%0%-63%n/an/an/a
Enliven Therapeutics ELVNUnited States$3.30B+7%n/an/an/an/an/a
Caliway Biopharmaceuticals 6919.TWTaiwan$3.32B-25%-54%-6,983%n/an/an/a
Sunshine Lake Pharma 6887.HKHong Kong$2.72B-7%+20%-3%n/an/an/a
HLB 028300.KSSouth Korea$2.69B-49%+26%-96%n/an/an/a
MBX Biosciences MBXUnited States$2.65B+70%n/an/an/an/an/a
Iovance Biotherapeutics IOVAUnited States$3.46B+111%+51%-61%n/an/an/a
Beijing Tiantan Biological Products 600161.SSChina$3.47B-13%-13%21%33.1×2.2%+12.5%
Xencor XNCRUnited States$2.58B+204%+34%-73%n/an/an/a
Xiamen Amoytop Biotech 688278.SSChina$2.56B-27%+18%27%15.0×-0.6%+36.0%
Disc Medicine IRONUnited States$3.55B+16%n/an/an/an/an/a

Questions

Who are ADMA Biologics's main competitors?
Named competitors: CSL Behring (private or unlisted), Grifols (GRF.MC), Takeda (4502.T), Kamada (KMDA). The cockpit's measured peer set (industry) also includes Telix Pharmaceuticals (TLX.AX), Dyne Therapeutics (DYN), Denali Therapeutics (DNLI), Rubicon Research (RUBICON.NS), Xeris Biopharma (XERS), XtalPi (2228.HK).
Is ADMA Biologics expensive compared with its peers?
On forward p/e it trades at 16.7× against a peer median of 29.9×, 4th cheapest of 9 in its peer set. For today's price to make sense, revenue must grow about -1% a year for seven years (Req g). Recent delivered growth is +65%, so the hurdle is -65 pp: the price already allows for a slowdown.
How has ADMA Biologics stock performed?
Over six months to 18 Nov 2026 the shares returned +58.4% against -2.0% for the median peer; over one year -12.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.